|Day Low/High||77.80 / 78.39|
|52 Wk Low/High||77.63 / 113.31|
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.
Leerink trimmed its price target on Gilead Sciences (GILD) stock today as it anticipates lower revenue from HIV sales in the future.
Gilead Sciences, Inc. (Nasdaq:GILD) announced today that Kelly A.
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Truvada ® (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination...
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Analysts at Piper Jaffray said in a note this morning that Gilead Sciences (GILD) can create value without splitting its HIV and HCV franchises.
A recent note from RBC Capital on Gilead gained a lot of attention as well as a pickup in call-option purchases.
Piper Jaffray analysts say Gilead Sciences (GILD) could be moving toward a 'modest' multiple.
Big gainers last week, and a roundup of portfolio changes.
Prescription data for Gilead's (GILD) hepatitis-C treatments were mixed for the week ended August 5, according to Leerink.
RBC Capital analysts say this would free 'trapped value' on drug treatments.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Leerink analysts said Gilead's (GILD) sales decline could be the result of several factors.
Cramer shares his views on the winners and losers of this earnings season. Comcast, Idexx Laboratories and Zoetis are among the stocks discussed.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.
The sector seems to be rebounding after tumbling by more than 40%.
TheStreet highlights 3 stocks pushing the health services industry higher today.
The company also could look to acquire a smaller biotech company, though likely not Medivation.